Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2023; 12(02): 093-099
DOI: 10.1055/s-0043-1771445
Original Article

Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income Countries

Purvish Mahendra Parikh 
1   Department of Clinical Hematology, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India
,
Shyam Aggarwal
2   Department of Medical Oncology, Sir Gangaram Hospital, New Delhi, India
,
Ghanashyam Biswas
3   Department of Medical Oncology, Sparsh Hospitals and Critical Care Private Ltd., Bhubaneswar, Odisha, India
,
Seema Gulia
4   Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India
,
Vivek Agarwala
5   Department of Medical Oncology, Narayana Superspeciality Hospital and Cancer Institute, Kolkata, West Bengal, India
,
Maheboob Basade
6   Department of Medical Oncology, Saifee Hospital, Mumbai, Maharashtra, India
,
P.N. Mohapatra
7   Department of Medical Oncology, Apollo Cancer Center, Kolkata, West Bengal, India
,
Krishna Muddu Vamshi
8   Department of Medical Oncology, AIG Hospital, Hyderabad, Telangana, India
,
Arun Warrier
9   Department of Medical Oncology, Aster Medicity, Cochin, Kerala, India
,
Krishna Prasad 
10   Department of Medical Oncology, Mangalore Institute of Oncology, Mangalore, Karnataka, India
,
Partha Roy
11   Department of Medical Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, Assam, India
,
M.V. Chandrakant
12   Department of Medical Oncology, Narayana Hospital, Howrah, West Bengal, India
,
Hemant Malhotra 
13   Department of Medical Oncology, Mahatma Gandhi Medical College Hospital, Jaipur, Rajasthan, India
,
Sachin Hingmire 
14   Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
,
Davinder Paul
15   Department of Medical Oncology, Fortis Hospital, Ludhiana, Punjab, India
,
Vashista Maniar
16   Department of Medical Oncology, Mumbai Oncocare Center, Mumbai, Maharashtra, India
,
Alok Gupta
17   Department of Medical Oncology, Medanta Hospital, Lucknow, Uttar Pradesh, India
,
Soumya S. Panda
18   Department of Medical Oncology, The Institute of Medical Sciences and Sum Hospital, Bhubaneswar, Odisha, India
,
Aseem Samar
19   Department of Medical Oncology, Bhagwan Mahavir Cancer Hospital & Research Center, Jaipur, Rajasthan, India
,
Nitesh Rohatgi
20   Department of Medical Oncology, Fortis Cancer Institute, Delhi, India
,
Satya Dattatreya
21   Department of Medical Oncology, Renova Soumya Hospital, Secundarabad, Telangana, India
,
Manjunath Krishnamurthy
4   Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra, India
,
Raja Thirumalairaj
22   Department of Medical Oncology, Apollo Cancer Center, Chennai, Tamil Nadu, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Zoom Image
Purvish M. Parikh

Cancer-associated anemia (CAA) remains a major unmet need that compromises overall survival (OS) and quality of life (QoL). Currently, available guidelines do not take into consideration the unique challenges in low- and middle-income countries (LMIC). Our CAA patients have to battle preexisting impaired nutritional status, depleted body iron stores, financial limitations, and difficulty in having easily accessible affordable healthcare. Hence, we fulfilled the need of guidelines for LMIC. A group of subject experts were put together, given background literature, met in a face-to-face discussion, voted using Delphi process, and finally agreed on the contents of this guideline document. As many as 50% of cancer patients will have significant anemia (hemoglobin < 10 g/dL) at initial diagnosis. It is most commonly seen with gastrointestinal malignancies, head and neck cancers, and acute leukemias. The hemoglobin falls further after initiation of cancer directed therapy, due to chemotherapy itself or heightened nutritional deficiency. Its evaluation should include tests for complete blood count, red blood cell morphology, reticulocyte count, Coombs test, and levels of vitamin B12 and folic acid. Iron status should be monitored using test to measure serum iron, total iron binding capacity, transferring saturation, and serum ferritin levels. A minimum of 50% of cancer patients with anemia require iron supplements. The preferred mode of therapy is with intravenous (IV) iron using ferric carboxymaltose (FCM). Most patients respond satisfactorily to single dose of 1000 mg. It is also safe and does not require use of a test dose. Significant anemia is found in at least half of all cancer patients in India, South Asian Association for Regional Cooperation region, and other LMIC countries. Its awareness among healthcare professionals will prevent it from remaining undiagnosed (in up to 70% of all cancer patients) and adversely affecting OS and QoL. The benefits of treating them with IV iron therapy are quick replenishment of iron stores, hemoglobin returning to normal, better QoL, and avoiding risk of infections/reactions with blood transfusions. Many publications have proven the value of single-dose FCM in such clinical situations. CAA has been proven to be an independent prognostic factor that adversely affects both QoL and OS in cancer patients. Use of FCM as single IV dose of 1000 mg is safe and effective in the majority of patients with CAA.

Keywords

iron deficiency - ferric carboxymaltose - erythropoietin - quality of life - well-being


Publication History

Article published online:
15 September 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References:

  • 1 Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15 (06) 979-986
    CrossrefPubMedSearch in Google Scholar
  • 2 Prabhash K, Nag S, Patil S, Parikh PM. Optimising management of cancer related anemia. Indian J Cancer 2011; 48 (01) 1-10
    CrossrefPubMedSearch in Google Scholar
  • 3 Barrett-Lee PJ, Ludwig H, Birgegård G. et al; European Cancer Anaemia Survey Advisory Board and Participanting Centers. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 2006; 70 (01) 34-48
    CrossrefPubMedSearch in Google Scholar
  • 4 Birgegård G, Aapro MS, Bokemeyer C. et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005; 68 (Suppl. 01) 3-11
    CrossrefPubMedSearch in Google Scholar
  • 5 Bremberg ER, Brandberg Y, Hising C, Friesland S, Eksborg S. Anemia and quality of life including anemia-related symptoms in patients with solid tumors in clinical practice. Med Oncol 2007; 24 (01) 95-102
    CrossrefPubMedSearch in Google Scholar
  • 6 Biswas G, Pandey A, Ghadyalpatil N. et al. Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: a real-world clinical practice audit. South Asian J Cancer 2020; 9 (01) 59-61
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104 (08) 2263-2268
    CrossrefPubMedSearch in Google Scholar
  • 8 Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96 (03) 823-833
    CrossrefPubMedSearch in Google Scholar
  • 9 Sundriyal D, Nayak PP, Arya L, Walia M, Saha R. Evaluation of iron status in patients of solid organ malignancies: study from a cancer research centre. Indian J Surg Oncol 2020; 11 (01) 56-59
    CrossrefPubMedSearch in Google Scholar
  • 10 NCCN 2011 guidelines. Accessed June 24, 2023 at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
  • 11 Revicki DA, Brown RE, Feeny DH. et al. Health-related quality of life associated with intravenous iron in patients with cancer-associated anemia. Oncologist 2007; 12 (06) 741-749
    Search in Google Scholar
  • 12 Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91 (12) 2214-2221
    CrossrefPubMedSearch in Google Scholar
  • 13 Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of I.V. iron. Ann Oncol 2012; 23 (08) 1954-1962
    CrossrefPubMedSearch in Google Scholar
  • 14 Aapro M, Beguin Y, Bokemeyer C. et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2021; 32 (04) 508-521
    Search in Google Scholar
  • 15 Gafter-Gvili A, Steensma DP, Auerbach M. Should the ASCO/ASH Guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated?. J Natl Compr Canc Netw 2014; 12 (05) 657-664
    CrossrefPubMedSearch in Google Scholar
  • 16 Aapro M, Beguin Y, Bokemeyer C. et al; on behalf of the ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer. . ESMO Clinical Practice Guidelines. Annals of Oncology 2018; 29 (Suppl. 04) 96-110
    CrossrefPubMedSearch in Google Scholar
  • 17 Hufnagel DH, Mehta ST, Ezekwe C, Brown AJ, Beeghly-Fadiel A, Prescott LS. Prevalence of anemia and compliance with NCCN guidelines for evaluation and treatment of anemia in patients with gynecologic cancer. J Natl Compr Canc Netw 2021; 19 (05) 513-520
    CrossrefPubMedSearch in Google Scholar
  • 18 Link H, Schmitz S. Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany. Onkologie 2013; 36 (05) 266-272
    PubMedSearch in Google Scholar
  • 19 Reeves DJ, Quebe AK, Patel R. The ESA APPRISE Oncology Program: a history of REMS requirements, a review of the data, and an approach to compliance in the hospital. P&T 2011; 36 (07) 423-433
    Search in Google Scholar
  • 20 Aggarwal S, Vaid A, Ramesh A. et al. Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling. South Asian J Cancer 2018; 7 (02) 96-101
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Parikh PM, Narayanan P, Vora A. et al. Conflict of interest disclosure and interpretation - rest assured the medical professional in the audience is perceptive, alert and smart. Int J Med Sci 2019; 71: 4-8
    Search in Google Scholar
  • 22 Parikh PM, Sharatchandra Hingmire S, Patil B. et al. Oncology Gold Standard™ consensus statement on counselling patients for molecular testing and personalized cancer care. Int J Mol Immuno Oncol 2017; 2: 47-57
    CrossrefSearch in Google Scholar
  • 23 Niederberger M, Spranger J. Delphi technique in health sciences: a map. Front Public Health 2020; 8: 457
    CrossrefPubMedSearch in Google Scholar
  • 24 Noronha V, Joshi A, Patil VM. et al. Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents. Asia Pac J Clin Oncol 2018; 14 (02) e129-e137
    CrossrefPubMedSearch in Google Scholar
  • 25 Naeim A, Henning DJ, Becker PS. et al. The role of iron in cancer-related anemia: a report from the National Comprehensive Cancer Network Myeloid Growth Factors Panel. J Natl Compr Canc Netw 2021; 19 (01) 1-16
    PubMedSearch in Google Scholar
  • 26 Parikh PM, Gupta N, Rangarajan B. et al. Real-world use of intravenous iron in cancer patients with iron deficiency anemia: results from the HEMATOCRIT study. Oncologist 2019; 24 (08) 1027-1034
    PubMedSearch in Google Scholar
  • 27 Bokemeyer C, Aapro MS, Courdi A. et al; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43 (02) 258-270
    CrossrefPubMedSearch in Google Scholar
  • 28 Bohlius J, Bohlke K, Castelli R. et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol 2021; 39 (08) 867-883
    PubMedSearch in Google Scholar
  • 29 Parikh PM, Madkaikar M, Ramanathan P. et al. Safety and efficacy of iron sucrose in patients with cancer-related iron deficiency anemia: a randomized, controlled study. J Clin Oncol 2012; 30 (suppl): Abstract 14014
    CrossrefSearch in Google Scholar
  • 30 Parikh PM, Vora AR, Patel HA. et al. Comparative study of intravenous iron sucrose and oral iron in treatment of iron deficiency anemia in cancer patients on chemotherapy. Indian J Med Paediatr Oncol 2014; 35 (02) 105-109
    Search in Google Scholar
  • 31 Henry DH, Dahl NV, Auerbach MA. Intravenous iron: a critical appraisal of its role in the treatment of iron deficiency anemia and implications for future research. Oncologist 2011; 16 (Suppl. 03) 15-26
    Search in Google Scholar
  • 32 Singh T, Gupta A, Mittal A. et al. Comparative study of intravenous iron sucrose and oral iron in cancer-associated anemia. Indian J Med Paediatr Oncol 2016; 37 (04) 223-226
    PubMedSearch in Google Scholar
  • 33 Bansal D, Bhakuni DS, Kalaivani M. et al. Comparative study of intravenous iron sucrose and oral iron therapy in the treatment of iron deficiency anemia in cancer patients undergoing chemotherapy. Indian J Med Paediatr Oncol 2017; 38 (03) 287-291f
    PubMedSearch in Google Scholar
  • 34 Srivastava A, Kumar R, Bhargava R. et al. Evaluation of efficacy and safety of intravenous iron sucrose in patients with cancer-related anemia. Indian J Med Paediatr Oncol 2017; 38 (02) 184-188
    Search in Google Scholar
  • 35 Steinmetz T, Beutel G, Steinmetz AP, Popp FC. Treatment of cancer-associated anemia with intravenous iron: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2021; 147 (05) 1277-1287
    Search in Google Scholar
  • 36 Steinmetz T, Tschechne B, Harlin O. et al. Ferric carboxymaltose in the treatment of iron deficiency anemia in oncology patients: a retrospective observational study. Onkologie 2011; 34 (06) 314-318
    Search in Google Scholar
  • 37 Gasche C, Ahmad T, Tulassay Z. et al. Ferric carboxymaltose for iron deficiency anemia in patients with inflammatory bowel disease: a randomized, controlled trial. Am J Gastroenterol 2013; 108 (05) 753-761
    Search in Google Scholar
  • 38 Reinisch W, Staun M, Tandon RK. et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013; 108 (12) 1877-1888
    CrossrefPubMedSearch in Google Scholar
  • 39 Koskenkorva TS, Peltola HT, Kekomäki R. et al. Ferric carboxymaltose administered as a single infusion for iron deficiency anemia in heavy non-menstruating women: a randomized controlled trial. Gynecol Oncol 2015; 137 (01) 107-112
    Search in Google Scholar
  • 40 Talboom K, Borstlap WAA, Roodbeen SX. et al; FIT collaborative group. Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled trial. Lancet Haematol 2023; 10 (04) e250-e260
    CrossrefPubMedSearch in Google Scholar
  • 41 Chardalias L, Papaconstantinou I, Gklavas A, Politou M, Theodosopoulos T. Iron deficiency anemia in colorectal cancer patients: is preoperative intravenous iron infusion indicated? A narrative review of the literature. Cancer Diagn Progn 2023; 3 (02) 163-168
    CrossrefPubMedSearch in Google Scholar
  • 42 Kennedy NA, Achebe MM, Biggar P, Pöhlmann J, Pollock RF. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. Int J Clin Pharm 2023; 45 (03) 604-612
    CrossrefPubMedSearch in Google Scholar
  • 43 Gluszak C, de Vries-Brilland M, Seegers V. et al. Impact of iron-deficiency management on quality of life in patients with cancer: a prospective cohort study (CAMARA study). Oncologist 2022; 27 (04) 328-333
    CrossrefPubMedSearch in Google Scholar
  • 44 Kim HY, Kim HY, Han HS. et al. Efficacy and safety of ferric carboxymaltose for iron-deficiency anemia in patients with gastrointestinal cancer: a randomized, open-label, multicenter study. Ann Oncol 2021; 32 (01) 117-125
    Search in Google Scholar
  • 45 Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in the treatment of iron deficiency anemia. Ther Adv Hematol 2015; 6 (05) 228-237
    PubMedSearch in Google Scholar
  • 46 Bhandari S, Duggal R, Kumar R, Mishra A, Rastogi N. Intravenous iron in geriatric patients with cancer-associated anemia: an experience from tertiary care center in India. J Geriatr Oncol 2019; 10 (01) 138-140
    PubMedSearch in Google Scholar
  • 47 Johansson PI, Rasmussen AS, Thomsen LL, Holmboe S, Brinch K, Kehlet H. Intravenous iron supplementation to patients with cancer-related anemia undergoing chemotherapy causes significant improvements in fatigue and quality of life. J Clin Oncol 2001; 19 (21) 3781-3787
    Search in Google Scholar
  • 48 ChatGPT Feb 13 Version. Accessed June 24, 2023 at: https://chat.openai.com/chat#:~:text=Open%20sidebar,help%20us%20improve